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The toxicity of an abnormally long polyglutamine [poly(Q)] tract within specific proteins is the molecular
lesion shared by Huntington’s disease (HD) and several other hereditary neurodegenerative disorders. By a
genetic screen in Drosophila, devised to uncover genes that suppress poly(Q) toxicity, we discovered a
Drosophila homolog of human myeloid leukemia factor 1 (MLF1). Expression of the Drosophila homolog
(dMLF) ameliorates the toxicity of poly(Q) expressed in the eye and central nervous system. In the retina,
whether endogenously or ectopically expressed, dMLF co-localized with aggregates, suggesting that dMLF
alone, or through an intermediary molecular partner, may suppress toxicity by sequestering poly(Q) and/or
its aggregates.
INTRODUCTION
Excessive expansion of poly(CAG) tracts is associated with at
least eight human hereditary neurodegenerative disorders (1).
The expanded poly(CAG)s are translated to abnormally long
polyglutamine [poly(Q)] tracts in the affected gene products,
promoting their nuclear and/or cytoplasmic aggregation, and
inducing cellular toxicity (2–4). In order to understand and
possibly cure these diseases, the molecular components of the
pathways involved in the associated neuronal degeneration have
been investigated. These include components of protein folding
(5–7), protein degradation (8,9), gene expression (10–17) and
programmed cell death (18–20), as well as interacting proteins
(21–23), neurotransmitters and their receptors (24–26).
The approach in this study is to search for novel genetic
factors that suppress the cellular toxicity. Several Drosophila
models have recapitulated the abnormal protein aggregation
and neuronal toxicity associated with poly(Q) disorders
(27–31). Independently of the context of the poly(Q) tract, be
it in a full-length ataxin-1 in spinocerebellar ataxia type 1 or
SCA1 (31), or in a truncated ataxin-3 in SCA3 (27), or in
huntingtin in HD (28), or in a quasipure 108Q tract (29) or in a
quasipure 127Q tract (30), expanded poly(Q) tracts in the
disease size range consistently showed higher propensity to
produce cellular inclusions and toxicity. However, perhaps
based on differences in residues flanking the poly(Q) tract,
these transgenic constructs vary in the manner in which
they genetically interact with other, exogenously or endogen-
ously expressed, genes. For instance, while the baculovirus
anti-apoptotic gene P35 partially suppressed the eye phenotype
in a SCA3 Drosophila model (27), it had no detectable effect in
flies expressing a truncated huntingtin with an expanded
poly(Q) (28). Similarly, either alone or in combination with the
suppressor P-element reported here, P35 had no effect on the
eye phenotype produced by 127Q (P. Kazemi-Esfarjani and
S. Benzer, unpublished data).
In contrast to the latter observations, screens for dominant
modifiers of poly(Q) toxicity, using either a full-length ataxin-1
82Q or plain 127Q polypeptide, in both cases identified
dHDJ1, a Drosophila ortholog of Hsp40/HDJ1, a human co-
chaperone protein (30,31). When overexpressed, dHDJ1
suppresses poly(Q) toxicity in the fly eye. Genetic and
molecular analysis of this protein revealed that its N-terminal
J domain mediates its suppressor activity via Hsp70, a
chaperone involved in protein folding (32). Overexpression
of Hsp70 was also able to suppress the toxicity of a truncated
ataxin-3 with an expanded poly(Q) tract (33). Of considerable
interest is the fact that overexpression of Hsp70 also suppressed
the toxicity of a-synuclein, associated with Parkinson’s disease
(34). Therefore, other modifier genes, such as the one reported
here, might be relevant as therapeutic targets in other diseases
with protein folding lesions.
As we have previously reported, the same genetic screen with
127Q identified another suppressor gene that encodes a protein
with a C-terminal J domain and seven tetratricopeptide repeat
(TPR) motifs (30). TPR motifs form suitable protein–protein
interfaces (35). The human ortholog, hTPR2, was earlier
discovered, in a two-hybrid screen, as a protein interactor of the
guanine triphosphatase (GTPase)-activating protein-related
domain (GRD) of neurofibromin, the neurofibromatosis type
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1 (NF1) gene product (36). Later, independently, in another
two-hybrid screen, hTPR2 was found to interact with hRad9,
a 30 to 50 exonuclease and a proapoptotic and cell cycle check-
point protein (37). Both in vivo and in vitro, this interaction was
mediated through the TPR motifs and was greatly enhanced
by the deletion or point mutation of the hTPR2 C-terminal J
domain. Those observations open new avenues for research on
the mechanism of suppression by dTPR2.
Identification of the genes and biochemical pathways that modify
poly(Q) toxicity in Drosophila would potentially provide genetic
targets for designing and testing therapeutic agents. This was
demonstrated by suppression of poly(Q) toxicity in Drosophila by
pharmacological inhibition of the deacetylation process of the
histones involved in chromosomal structure and gene transcription
(38). As an ongoing search for such modifier genes, we report here
an entirely different gene that, similar to those mentioned above,
suppresses poly(Q) toxicity without preventing the formation of
intracellular inclusions. Interestingly, the homologous gene in
humans is associated with a neoplastic disease.
RESULTS
Cellular toxicity by expanded poly(Q)s
As before (30), P-element constructs were designed to express
poly(Q) tracts of various lengths (20Q, 63Q and 127Q),
carrying hemagglutinin (HA) protein tags on their C-terminal
ends as an immunogenic marker. The constructs were
microinjected into early embryos and transgenic lines were
established. In vivo expression was regulated by the yeast
transcription factor GAL4 acting on yeast upstream activating
sequences (UAS) (30,39). To activate expression, these
transgenic flies were crossed with other transgenic flies
expressing GAL4 in the eye, using the promoter GMR (glass
multimer reporter) (40–42), which is active in all retinal cells,
from the time of their differentiation throughout adulthood
(P. Kazemi-Esfarjani and S. Benzer, unpublished data). In a
separate set of experiments, we used the neuron-specific driver
Appl–GAL4 to express poly(Q) in the nervous system (43).
Control flies with a heterozygous insertion of GMR–GAL4
alone had fully developed eyes (Fig. 1A). When combined with
a chromosome carrying UAS and a small poly(CAG) repeat
(20Q), there was no evident change (Fig. 1B). Using an anti-
HA antibody, immunohistological examination of head cryo-
sections of 1-day-old flies carrying GAL4 alone, or GAL4 plus
20Q, revealed no poly(Q) aggregates, consistent with the
experience of others (27–31). However, it should be noted that
the 20Q peptide was also undetectable on western blots. In
contrast, 63Q and 127Q flies had severely collapsed eyes,
lacking pigmentation; in sections, anti-HA antibody revealed
abundant poly(Q) clumps in the eye (Fig. 1C and D). As a
control for non-specific suppression effects, the retina expres-
sing lacZ in addition to 127Q was equally defective (Fig. 1E).
Milder toxicity by longer sequences flanking
the poly(Q) repeat
In mammalian cell culture systems, expanded poly(Q)s of a
given length are less toxic in the context of a larger protein
(44–46). To verify whether the same applies to flies, the eyes of
flies expressing 20Q and 127Q were compared with eyes
expressing the same repeat length as part of a truncated form of
the Drosophila gene prospero, a neurogenic gene involved in
neuronal fate specification in the central and peripheral
nervous systems, which contains a segment coding for a 20Q
poly(Q) tract ( pros20Qtr) [but does not share any other
similarity with known poly(Q) disease genes] (47,48). Flies
expressing either 20Q or pros20Qtr had apparently normal eye
structure and pigment distribution (Fig. 2A and C). When flies
expressing 127Q and pros127Qtr were compared, the latter
showed milder toxicity, as judged by more pigmentation and
less disturbed external structure (Fig. 2B and D). With
truncated prospero constructs having a longer poly(Q) length
( pros223Qtr), a level of phenotypic severity similar to that of
the expanded pure poly(Q) 127Q could be achieved (Fig. 2E).
These results were confirmed with three independent transgenic
lines for each construct. Therefore, in the fly, as in mammals,
attenuation of poly(Q) toxicity increases with increasing size of
the non-repeat portion of a protein.
Identification of dmlf suppressor gene
in a genetic screen
To screen for genes that suppress the toxicity of 127Q, the
GMR–GAL4/UAS–127Q flies were crossed to 7000 de novo
generated, random P-element insertions (30). To enhance
expression, the P-elements contained 14 tandem UAS ele-
ments, which, in the presence of GAL4, drive the expression of
downstream genomic sequences (49). Hence, if there is a gene
downstream of a P-element insertion that codes for a modifier
gene, it will be activated and cause a change in the eye
phenotype.
Here, we describe a suppressor (EU2490, the 2490th newly
generated P-element insertion tested), which dramatically
counteracts the external eye and pigmentation defect caused
by 127Q (Fig. 3C). Internal improvement was also seen in
cryosections of the eye. Plasmid rescue of the P-element was
performed and the DNA flanking the 30 end of the P-element
was sequence (50). A BLAST search on the Berkeley
Drosophila Genome Project (BDGP) server identified several
expressed sequence tags (ESTs) with corresponding cDNA
clones. A stretch of  220 bp of the genomic DNA was 97%
identical to the DNA sequence beginning 54 bp downstream of
a predicted ATG start site of an open reading frame (ORF) in a
cDNA clone, GH20101, from an adult head library (BDGP and
Research Genetics). The ORF in GH20101 is 822 bp long and
lies within a 1745 bp cDNA insert with 74 bp 50-untranslated
region (UTR) 849 bp 30-UTR and an 18-base poly(A) tail
(GenBank accession no. AY037049). The predicted translation
product of the ORF is a 273-amino-acid protein with a
molecular weight of 30 kDa, and it is homologous to the 268-
amino-acid predicated protein, human myeloid leukemia factor
1 (hMLF1) (51), with 32% identity and 49% similarity.
Therefore, it is referred to as Drosophila myeloid leukemia
factor (dMLF) (52). Recently, in a yeast two-hybrid screen,
dMLF protein was shown to interact with an N-terminal
segment of Drosophila DNA replication-related element-
binding factor (DREF) (52). However, the plasmid that
expressed dMLF (pACT1-2) (52), isolated from a third
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Figure 1. Toxic effect of expanded poly(Q)s in the fly eye. SEM, scanning electron microscopy; FITC, frozen horizontal sections labeled with antibody to the HA
tag on 20Q and 127Q peptide (green); FITC þ DAPI, double exposure with DAPI to stain nuclei (blue). (A) Control, expressing GAL4 regulated by GMR, the
eye-specific enhancer/promoter, in the absence of 127Q. The red pigmentation is due to expression of the whiteþ gene marker on the GMR P-element. No aggre-
gates are observed with FITC. DAPI shows a relatively normal arrangement of nuclei. (B) Flies carrying heterozygous insertions of UAS–20Q and GMR–GAL4.
As in (A), the eyes appear normal. Note that we have been unable to detect the 20Q peptide on western blots and in frozen sections. (C and D) Flies carrying
heterozygous insertions of UAS–63Q or UAS–127Q together with GMR–GAL4. The eyes have roughly normal sizes, but are severely malformed and lack
pigmentation. Due to severe retinal degeneration and cell loss, the eyes lack structural support. Therefore, during embedding procedures and SEM, they collapse.
FITC shows numerous fluorescent poly(Q) aggregates, mostly localized to nuclei, as seen by overlap with DAPI. (E) Negative control for non-specific suppressor
effects. Flies carrying heterozygous insertions of UAS–127Q and UAS–lacZ (the gene for Escherichia coli b-galactosidase) together with GMR–GAL4. Expression
of b-galactosidase did not improve the phenotype.
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instar larva cDNA library, contained a longer ORF predicting a
309-amino-acid protein. While otherwise identical, it is 36
residues longer at the C-terminal end than the 273-amino-acid
protein predicted by the GH20101 plasmid in this study, and 41
residues longer than the 268-amino-acid protein predicted by
hMLF1 cDNA.
To investigate the possibility that the differences might be due
to alternative splicing, a second, independent clone, LD47427,
isolated from an embryo cDNA library, was sequenced, and all
three cDNA sequences were matched against the genomic
sequence of the dmlf gene (53). As with the pACT1-2 plasmid
(52), LD47427 harbors an ORF that codes for a dMLF with 309
amino acids, and is generated by skipping a potential pre-
mRNA splice junction in the genomic DNA. On the other hand,
the ORF in GH20101 is generated using this early junction,
resulting in splicing of an additional exon between the third and
fourth exons in pLD47427. The stop codon that appears 10 bp
from this alternative splice site results in a shorter ORF coding
for 273 amino acids. Based on northern blot analysis, dmlf
mRNA levels are high in unfertilized eggs, early embryos,
pupae and adult males, and relatively low in adult females and
larvae (52). Therefore, as dmlf mRNA is differentially
expressed, it might also be alternatively spliced in embryo
(LD47427) and third instar larva (pACT1-2) versus adult head
(GH20101). A more comprehensive analysis is underway to
clarify this aspect of dmlf expression.
Suppression of poly(Q) toxicity by transgenic
expression of dmlf
To confirm whether the expression of dMLF is responsible
for the suppression effect, the cDNA insert in GH20101 was
placed in the same kind of P-element vector as UAS–127Q,
and transgenic line were established. Three independently
established lines, each carrying a heterozygous autosomal
insertion of UAS–dmlf in the presence of GMR–GAL4/UAS–
127Q, reproduced the improvement in external eye structure
and pigmentation to an even greater extent than did the original
P-element insertion (Fig. 3D and E). Similar suppression was
obtained from the cDNA insert in LD47427 (not shown).
Again, the internal eye structure was only slightly improved.
We therefore tried higher doses of the suppressor gene. Three
different transgenic lines were established, each carrying UAS–
dmlf transgenic insertions on both the second and third
chromosomes. These improved both the external and internal
eye structures to almost normal (Fig. 3F). Nevertheless, as with
the two suppressor genes described previously (30), numerous
fluorescent aggregates were still present in the eye. Thus,
despite the great reduction in toxicity, with none of these
suppressors was the aggregation of poly(Q) prevented. Rather,
they appeared to reduce the toxicity of the poly(Q), or enhance
the ability of the cells to resist their toxic effect.
To investigate the overexpression effect of dmlf on the retinas
expressing pros20Qtr or pros127Qtr, immunofluorescence
experiments were performed as above. With respect to tissue
morphology and the locations of DAPI-stained nuclei, retinas
in which pros20Qtr was expressed appeared normal (Fig. 4A).
As with 20Q alone, no aggregates were visible with anti-HA-
dependent fluorescence staining. Nevertheless, the retinas of
flies accumulated enough protein to produce a strong HA
signal on western blots. Retinas that express pros20Qtr in the
presence of two doses of dmlf transgenes also had normal
morphology, except for some displacement of nuclei, perhaps
as a result of dMLF interference with developmental processes
(Fig. 4B). Compared with retinas expressing pros20Qtr,
retinas that express pros127Qtr were thinner and had defective
tissue morphology (Fig. 4C). As compared with pure 127Q,
they also appeared to generate a smaller number of anti-
Figure 2. The effect of protein context size on poly(Q) toxicity. The poly(Q) tracts in 20Q and 127Q are flanked by 8 amino acids on the N-terminal side and 13
amino acids on the C-terminal side. The poly(Q) tracts in the truncated prospero constructs, PROS20Qtr, PROS127Qtr and PROS223Qtr, are flanked by 33 amino
acids on the N-terminal side and 369 amino acids on the C-terminal side.(A) The fly expressing 20Q, driven by GMR–GAL4, the eye-specific enhancer/promoter.
The red pigmentation is due to expression of the whiteþ gene marker on the P-element carrying the transgene. The eyes appear normal.(B) The fly expressing 127Q
peptide driven by GMR–GAL4. The eye has roughly normal size, but is severely malformed and lacks pigmentation. (C) The fly expressing pros20Qtr. As with
20Q in (A), the eyes appear normal. (D) The fly expressing pros127Qtr. The eye is only mildly degenerated, with a slight loss of pigmentation. (E) The fly
expressing pros223Qtr. In the context of truncated PROSPERO protein, expanded poly(Q)s can still exert a severe toxic effect, but only with relatively larger
repeat sizes.
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Figure 3. Genetic suppression of the toxic effect of 127Q in the fly eye by dMLF. SEM, scanning electron microscopy; FITC, frozen sections labeled with antibody
to the HA tag on 127Q peptide (green); FITC þ DAPI, double exposure with DAPI to stain nuclei (blue). (A) Control, expressing GAL4 regulated by GMR, the
eye-specific enhancer/promoter, in the absence of 127Q. The red pigmentation is due to expression of the whiteþ gene marker on the GMR P-element. No aggre-
gates are observed with FITC. DAPI shows a relatively normal arrangement of nuclei. (B) Flies expressing the 127Q peptide driven by GMR–GAL4. The eye has
roughly normal size, but is severely malformed and lacks pigmentation. Due to severe retinal degeneration and cell loss, the eyes lack structural support. Therefore,
during embedding procedures and SEM, they collapse. FITC shows numerous fluorescent poly(Q) aggregates, mostly localized to nuclei, as seen by overlap with
DAPI. (C) Suppressor P-element insertion EU2490 partially preserves the external eye structure and pigmentation. FITC and DAPI stains show slightly improved
internal retinal structure. (D and E) Flies carrying a transgenic insertion of dmlf cDNA, corresponding to the gene downstream of the EU2490 P-element insertion,
either on chromosome 2 or on chromosome 3, confirm the identity of the suppressor gene as dmlf. (F) Double dosage of dmlf expression, achieved by combining
both the chromosome 2 and chromosome 3 transgenes. The eye structure and pigmentation are almost completely preserved, although the poly(Q) nuclear
inclusions are still present. The presence of some spots that are HA-positive but DAPI-negative indicates that there are cytoplasmic inclusions as well.
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HA-positive, fluorescent aggregates, with the caveat that some
of the PROS127Qtr polypeptides might have lost their HA tags
owing to degradation of a 360-amino-acid stretch separating
the poly(Q) tract and the HA epitope tag. As negative controls
for the suppression effect, neither one nor two doses of a
modified form of lacZ, coding for a b-galactosidase contain-
ing a nuclear localization signal, expressed together with
pros127Qtr, had any apparent protective effect (Fig. 4D and E).
On the other hand, when a single dose of dmlf transgene was
co-expressed with pros127Qtr, the retinas were preserved
Figure 4. The effect of dMLF overexpression in the presence or absence of PROS127Qtr, a truncated PROSPERO with a 127Q tract, with a milder toxicity. Anti-
HA þ FITC, frozen sections labeled with antibody to the HA tag on the C-terminal end of PROS127Qtr peptide (green); anti-ELAV þ Cy3, antibody to ELAV, a
neuron-specific nuclear protein, which exclusively labels the photoreceptor nuclei; DAPI, to stain nuclei (blue). (A and B) Control, expressing GAL4 regulated by
GMR, the eye-specific enhancer/promoter, in the presence of only PROS20Qtr, a truncated PROSPERO containing a 20Q tract (non-disease repeat range), or
together with two doses of the transgenic dmlf. No aggregates are observed with FITC in either type of flies. DAPI shows relatively normal arrangement of nuclei in
the presence of PROS20Qtr alone, which appeared to be slightly disturbed with the addition of two doses of dmlf transgene. (C) Flies expressing the PROS127Qtr
polypeptide driven by GMR–GAL4. The retina is thinner and a few fluorescent poly(Q) aggregates are visible. (D and E) As controls, one or two doses of a lacZ
gene, coding for a modified form of the E. coli b-galactosidase, containing a nuclear localization signal, has no apparent suppression effect on PROS127Qtr
toxicity. (F, G and H) Flies carrying a transgenic insertion of dmlf cDNA, corresponding to the gene downstream of the EU2490 P-element insertion, on chromo-
some 2 or on chromosome 3, or on both chromosomes. Compared with its effect in flies expressing 127Q (Fig. 3), even one transgenic dmlf insertion is sufficient
to protect the eye against the toxic effects of PROS127Qtr. (I, J and K) Retinas of control flies transgenic for GMR–GAL4 alone, or with one or two doses of
UAS–lacZ. The number of nuclei appears to be normal, albeit somewhat misplaced due to a high level of GMR–GAL4 expression. (L, M and N) Retinas of the
flies transgenic for GMR–GAL4 and one or two doses of UAS–dmlf. The number and location of nuclei are qualitatively similar to controls (i.e. I, J and K).
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(Fig. 4F and G). When two doses of dmlf transgenes were co-
expressed with pros127Qtr, the retinas were similarly preserved
as with a single dose (Fig. 4H).
We examined whether dmlf overexpression has a detrimental
effect on the cellular differentiation and development of the
retina by assessing the number and location of the nuclei. The
retinas were labeled with both anti-ELAV, an antibody raised
against a neuron-specific nuclear protein, and DAPI to stain
nuclei. In controls transgenic for GMR–GAL4 alone, or
together with one or two doses of UAS–lacZ, the number of
nuclei and their locations were essentially normal. The few
misplaced nuclei were perhaps due to high levels of expression
of GMR–GAL4, which causes some deterioration in the
structure of the retina (Fig. 4I, J and K). In flies transgenic for
GMR–GAL4 together with one or two doses of UAS–dmlf,
similar numbers and localization of nuclei were observed
(Fig. 4L, M and N). Therefore, even at a high expression level,
dMLF may have little effect on retinal structure. Nonetheless,
additional quantitative analyses at higher resolution are
required to examine possible changes in the size and number
of nuclei when dMLF is overexpressed.
The specificity of dMLF suppression effect with
respect to poly(Q) protein type
As a first step towards verifying the application of dmlf
suppressor activity in human poly(Q) disorders, dmlf suppres-
sion was further tested on a mutant form of huntingtin (Htt), the
Huntington’s disease gene product. dmlf transgenic flies were
crossed to flies expressing a truncated form of huntingtin with
120 glutamines (HttQ120) (28). pros20Qtr and pros127Qtr
flies were also tested in this experiment. Plastic sections of eyes
of the resulting progeny were examined for the structure of
their ommatidia, the units of the retina containing eight
photoreceptors and their accessory cells. At 1 day of age, in the
presence of active (with GMR–GAL4 driver) or inactive
(without GMR–GAL4 driver; not shown) UAS transgenes for
lacZ, or one or two doses of dmlf, the retinas expressing
HttQ120 still maintained the arrangement of the facets or
ommatidia, indicated by the presence of hexagonal borders
containing the darkly stained circular forms of the photo-
receptor rhabdomeres (Fig. 5A–D). However, with HttQ120 at
1, 2 or 5 weeks of age, the arrangement of ommatidia
deteriorated, except in the presence of one or two doses of
active (i.e. with GMR–GAL4 driver) UAS–dmlf transgenes
(Fig. 5A–D). In the absence of GMR–GAL4 driver, UAS–dmlf
transgenes were completely ineffective (not shown). The flies
expressing pros20Q in the presence or absence of two doses of
transgenic dmlf, had a preserved arrangement of ommatidia,
even at 2 weeks of age (Fig. 5E and F). However, for
pros127Qtr, not with lacZ (Fig. 5H and I), but with dmlf (Fig. 5J
and K), the deterioration was stayed only in 1-day-old flies.
dmlf transgenes were not effective in preserving the eye
structure up to 2 weeks of age. (Note that the differences in the
orientation of the ommatidia among different panels are due to
the orientation of the photography and not to phenotypic
effects.) Therefore, the dmlf suppression effect is not restricted
to degeneration caused by pure poly(Q) polypeptides, but could
also suppress the relatively milder toxicity of HttQ120 over a
prolonged period, up to 5 weeks.
dMLF is also effective in the central nervous system
To see whether dMLF protects other neuronal tissues against
the deleterious effects of long poly(Q)s, we used the neuron-
specific driver Appl–GAL4, derived from the promoter region
of the gene for the Drosophila homolog of human amyloid
precursor protein (APP) (43). Appl is expressed exclusively in
postmitotic neurons of the central and peripheral nervous
system, from mid to late stages of embryogenesis onward (54).
Flies carrying Appl–GAL4 alone developed normally, and
survived for the full observation period of 20 days. The same
was true for three independent UAS–20Q insertions in the
presence of Appl–GAL4. UAS–63Q, however, had a strong toxic
effect. Of four independent transgenic lines tested, three were
pre-adult lethal, and one gave rise to only female adults. (Since
the Appl–GAL4 transgene was on the X chromosome, dosage
compensation may have produced higher expression in males,
resulting in greater toxicity.) Three UAS–127Q lines were all
pre-adult lethal in the presence of Appl–GAL4. Therefore, to test
for suppression of toxicity by dmlf, 63Q females were chosen,
using survival of adults versus age as a criterion.
In controls, with Appl–GAL4 alone (not shown) or expres-
sing one or two doses of lacZ, the flies remained vital at 20
days (Fig. 6). In sections of the brain and thoracic ganglion, no
anti-HA fluorescent staining was observed in these flies. Flies
carrying Appl–GAL4 plus a heterozygous insertion of UAS–
63Q, by day 12, became progressively lethargic, with almost all
dead by day 20. Flies first became unable to climb the walls of
the plastic vial, and died within a few hours. Anti-HA antibody
on cryosections of 1-day-old adult Appl–GAL4/UAS–63Q flies
revealed aggregates in the neuronal cell bodies of the cortices
surrounding the neuropils of the brain and the thoracic
ganglion. The fluorescent aggregates appeared to be almost
exclusively localized to neuronal cell bodies, as evident by co-
localization with staining by DAPI and the absence of anti-HA
stain in synaptic neuropil regions. In plastic sections stained
with toluidine blue, or in electron micrographs, no signs of
neuronal degeneration were visible in either the brain or the
thoracic ganglion, even in the last flies surviving up to 20 days.
Death may be due to dysfunction of the neurons associated
with poly(Q), rather than neurodegeneration, as has been in a
reported mouse model for Huntington’s disease and another for
spinal and bulbar muscular atrophy (3,55).
Expression of dmlf had a protective effect against 63Q on
survival. At day 20, 55% of flies expressing 63Q along with
dmlf were still active, while all of those expressing 63Q alone
(or with lacZ) had also died (Fig. 6). Expression of dMLF alone
from either one or two transgenes did not have any detectable
effect on survival up to 20 days. Therefore, dmlf can protect
against poly(Q) toxicity in neuronal tissues, as well as in the
eye, supporting use of the eye as a convenient morphological
index in screening for suppression of toxicity.
Examination of DREF in respect to poly(Q)
toxicity and its suppression
In a recent publication, yeast two-hybrid screens uncovered
dMLF as a protein binding to DREF, a transcription factor that
regulates several genes involved in cell proliferation and DNA
replication in Drosophila; the binding was verified by
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immunoprecipitation. Overexpression of dref in the eye caused
a rough eye phenotype, with the loss of eye bristles. When dmlf
was co-expressed with dref, the eyes were partially improved,
indicated by partial restoration of the number and size of eye
bristles, under scanning electron microscope (52). We therefore
performed experiments to investigate a possible interaction in
our system. In our hands, using light microscopy as in Figure 1,
overexpression of dref caused severe eye degeneration, with
loss of pigments. However, when flies with a UAS–dref
transgene on the second chromosome and one or two UAS–
dmlf transgenes on the third chromosome were crossed to
GMR–GAL4 flies, in neither case was there any evident
improvement in the pigmentation or the structure of the eyes in
the progeny.
We also tested for possible modification of eye degeneration
caused by 63Q by crossing the normal dref, or a dominant-
negative form of dref (UAS–dref CR1) (56), or the zerknu¨llt
gene (UAS–zen), a possible repressor of dref transcription and
Figure 5. Short- and long-term effects on morphology of the ommatidial array expressing with various poly(Q) constructs alone or together with dmlf. Fly heads
were fixed and embedded in plastic sections before tangential sectioning and staining with toluidine blue. Phase-contrast microscopy was performed with a Zeiss
100oil-immersion objective. Note that the differences in the orientation of the ommatidia among different panels are due to the orientation of the photography and
not to phenotypic effects. (A) These flies expressed a truncated mutant human huntingtin, coding for an N-terminal fragment composed of 262 amino acids that
includes a 120Q tract (HttQ120), driven by the GMR promoter. In addition, they expressed GAL4, also driven by the GMR promoter. By 1 week of age, the
ommatidia have already degenerated. (B) A UAS–lacZ transgene in the presence of GAL4 was not sufficient to preserve the ommatidia against HttQ120 toxicity
at 1, 2 or 5 weeks of age. (C) Expression of a single dose of a dmlf transgene was sufficient to preserve the ommatidia against HttQ120 toxicity at up to 5 weeks of
age. (D) Expression of two doses of dmlf transgenes, from two independent chromosomal insertion sites, preserved the ommatidia at 1, 2 and 5 weeks of age, and
the effect was dependent on the presence of GMR–GAL4. (E) Controls expressing GAL4 regulated by GMR, the eye-specific enhancer/promoter, in the presence
of only PROS20Qtr, a truncated PROSPERO containing a 20Q tract (non-disease repeat range). (F) Up to 2 weeks of age, expression of two doses of dmlf trans-
genes, from two independent chromosomal insertion sites, had no apparent morphological effects on the eyes expressing pros20Qtr. (G) Flies expressing the
pros127Qtr driven by GMR–GAL4. Even in the 1-day-old flies, the ommatidia had disintegrated. (H and I) As controls, one or two doses of a lacZ gene, coding
for a modified form of the E. coli b-galactosidase, containing a nuclear localization signal, had no apparent suppression effect on PROS127Qtr toxicity. (J and K)
These flies carried a transgenic insertion of dmlf cDNA, corresponding to the gene downstream of the EU2490 P-element insertion, on chromosome 3, or on both
chromosomes 2 and 3. In 1-day-old flies, even one transgenic dmlf insertion was sufficient to at least partially preserve the ommatidia in the presence of
pros127Qtr, although, at 2 weeks of age, even two doses of dmlf transgenes were not sufficient to preserve the ommatidia.
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activity (57). UAS–dref, UAS–dref CR1 or UAS–zen
were crossed to GMR–GAL4/UAS–63Q, and the progeny
were examined as above. No detectable effect was observed
(not shown).
Colocalization of dMLF with poly(Q) aggregates
To investigate the question of whether poly(Q) co-localizes
with dMLF, through direct or indirect protein–protein interac-
tion, we made transgenic flies to express dMLF with an
N-terminal Flag epitope tag in the eye, using GMR–GAL4.
Flies expressing dmlf–N-Flag alone, or together with 127Q,
pros20Qtr or pros127Qtr, were sectioned and labeled with anti-
Flag and anti-HA antibodies. In these experiments, 127Q was
directly expressed from a GMR-like promoter with five GLASS
response elements (5GR–127Q). The flies with this transgene
had a slightly milder phenotype than did GMR–GAL4/UAS–
127Q flies. In these flies, expressing dMLF–N-Flag produced a
wider retina for better localization of poly(Q) aggregates and
dmlf–N-Flag (Fig. 7A). As controls for subcellular localization
and suppression effects, the cytoplasmic and nuclear forms of
the lacZ gene product, b-galactosidase, were expressed either
alone or together with 127Q (Fig. 7B–E). Flag staining of flies
carrying dmlf–N-Flag alone was relatively uniform throughout
the retina (Fig. 7F, G and H). The same was true together with
pros20Qtr (Fig. 7I, J and K). However, in the presence of 127Q
or pros127Qtr transgenes, the staining was more punctuate, and
many aggregates appeared positive for both anti-HA and anti-
Flag antibodies (Fig. 7L–O). Using an anti-dMLF antibody
(52), endogenously expressed dMLF was similarly localized to
HA-positive aggregates in the retina (not shown).
To better visualize the co-localization of dMLF and 127Q
aggregates, confocal microscopy was performed using 5GR–
127Q or another construct with one GLASS response element
(1GR–127Q). In 1-day-old-adults, 1GR–127Q produces fewer
127Q aggregates with no morphologically detectable retinal
degeneration. In flies co-expressing from UAS–lacZ (nuclear)
and 1GR–127Q, confocal microscopy of the sections, double-
stained with anti-b-galactosidase and anti-HA antibodies,
showed that all aggregates were contained within the nuclei,
as indicated by the yellow signals and no green signals
(Fig. 8A). The sections of the flies co-expressing from UAS–
dmlf–N-Flag and 1GR–127Q, double-stained with anti-Flag
and anti-HA antibodies, showed that, as in Figure 7, the anti-
Flag antibody produces punctate staining, and most of them
overlap with anti-HA signals, as indicated by the yellow signals
(Fig. 8B). Furthermore, by scanning the entire diameter of
these double-stained aggregates at 0.5 mm intervals and by
examining each focal plane separately, it was clear that each
punctuate yellow signal (overlapping Cy3 and FITC signals)
was originating from a single aggregate. For comparison,
confocal micrographs of retinas coexpressing from UAS–
dmlf–N-Flag and 5GR–127Q were also included (Fig. 8C).
These observations together indicate that dMLF is recruited
into poly(Q) aggregates, either by directly interacting with
poly(Q) fragments or through one or more intermediary
proteins. This recruitment may play a part in the suppression
mechanism.
DISCUSSION
A dominant genetic screen resulted in the discovery that the
dmlf gene suppresses the toxicity of abnormally expanded
poly(Q)s. The suppression was effective for different poly(Q)
lengths, different sizes of polypeptides containing the poly(Q)
and different cell types in which they were expressed. These
include 63Q and 127Q [the quasipure poly(Q)s], PROS127Qtr
(composed of a 127Q tract within the 529 amino acids of the
PROSPERO C terminus), and HttQ120 (composed of a 120Q
Figure 5 continued.
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tract within 262 amino acids of the N terminus of human
huntingtin) (28). dmlf was effective in suppressing poly(Q)
toxicity both in the eye and in neurons of the central (and
peripheral) nervous system(s). When expressed alone, dmlf
had little or no detectable detrimental effect.
Examination of the in vivo co-localization of dMLF and poly(Q)
showed that endogenous and N-terminally Flag-tagged dMLF
appear in the same aggregates with HA-labeled 127Q or
PROS127Qtr. The transgenic dMLF might block various binding
sites of aggregated poly(Q), preventing the recruitment of other
cellular factors necessary for cell viability. This ‘sequestered
poly(Q)’ hypothesis could also provide a possible mechanism for
the suppression afforded by the chaperone Hsp70 (33) and the co-
chaperone protein dHDJ1/Hsp40 (30,32). Overexpression of a
single dose of dHDJ1 almost fully protected the eye morphology
against 127Q toxicity, even though numerous aggregates were still
Figure 6. Protective effect of dMLF in the nervous system. With expression of 63Q alone, or together with lacZ, driven by the Appl–GAL4 driver, flies began to die
by day 12, and almost all were dead by day 20. On the other hand, expression of dMLF in 63Q flies extends their lifespan, with about 55% still alive at day 20.
Control flies, with Appl–GAL4 and one or two doses of the nuclear UAS–lacZ or dmlf, were almost all active at the end of the experiment (day 20). Flies were
housed at 20 per vial, using three to eight vials for each combination of transgenic inserts. Every 4 days, the flies were transferred to new vials and the inactive or
dead flies were counted. These were defined by complete lack of movement or inability to climb onto the vial wall. Error bars indicate SEM.
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Figure 7. In vivo co-localization of epitope-tagged dMLF with expanded poly(Q) aggregates. (A) Expression of 127Q driven by a GMR-like enhancer/promoter
causes severe degeneration associated with the presence of HA-positive aggregates in a collapsed retina. (B and C) For comparison, expression of cytoplasmic or
nuclear b-galactosidase (stock no. 3955), encoded by the lacZ gene, showing the pattern of subcellular localization. (D and E) Neither form of lacZ could suppress
the degeneration caused by 5GR–127Q, and HA-positive aggregates are still visible. (F, G and H) In three independent transgenic lines, the localization of
N-terminally Flag-tagged dMLF expressed in the absence of poly(Q) proteins appears to be relatively uniform; though, some punctate staining is visible, especially
in the distal region of the retina. (I, J and K) In three independent transgenic lines, the localization of N-terminally Flag-tagged dMLF expressed in the presence of
PROS20Qtr still appears to be relatively uniform. (L–O) N-terminally Flag-tagged dMLF, expressed from four independent transgenic insertions, appear to form
aggregates in the presence of 127Q or PROS127Qtr, and some anti-Flag-positive inclusions appear to co-localize with anti-HA-positive ones.
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Figure 8. Confocal images demonstrating in vivo co-localization of epitope-tagged dMLF with expanded poly(Q) aggregates. (A) In 1-day-old adult flies, expres-
sion of 127Q from a 1GR–127Q transgene, containing a single GLASS response element in the enhancer/promoter region upstream of the 127Q DNA sequence,
produces fewer anti-HA-positive aggregates (FITC, green) and no morphologically detectable retinal degeneration as compared with GMR–GAL4/UAS–127Q.
Expression of nuclear b-galactosidase from the UAS–lacZ transgene in the same flies driven by GMR–GAL4 produces anti-b-galactosidase positive nuclear
stains (Cy3, red). The yellow signal resulting from superimposition of Cy3 and FITC signals indicates that all anti-HA positive aggregates are confined to nuclei.
(B) Both the 127Q (FITC, green) expressed from 1GR–127Q and N-terminally Flag-tagged dMLF (Cy3, red), expressed from UAS–dmlf–N-Flag, form aggregates.
When superimposed, many anti-HA- and anti-Flag-positive aggregates overlap, as indicated by the yellow signal. (C) For comparison, flies that express 127Q from
5GR–127Q and N-terminally Flag-tagged dMLF from UAS–dmlf–N-Flag are shown.
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present in the eye (30). Poly(Q) aggregates in transgenic flies
expressing a truncated Machado–Joseph/SCA3 disease gene
product, MJD/ataxin-3, with 78 glutamines, co-localized with a
transgenic human Hsp70 (33), as well as a transgenic Flag-tagged
dHDJ1 (32). Transgenic expression of Hsp70 or dHDJ1, or both
together, increased the solubility of the aggregates, without having
any detectable effect on their onset, size or number (32,33).
Therefore, it is possible that suppression is not achieved merely
through enhanced solubility of aggregates and with their removal
by protein degradation machinery, but by sequestering them.
The sequestered poly(Q) hypothesis may also account for
other observations. Ectopic expression of the transcriptional
regulators CBP (10,11,13), TAFP130 (12) or Sp1 (58,59) could
rescue the cells in culture, while other proteins are also affected
by, interact with or are recruited by mutant poly(Q) proteins or
their inclusions [e.g. the transcription factors TBP (60,61), p53
(13), CA150 (14), N-CoR (15), mSin3 (15) and CRX (62), as
well as CBP, TAFP130 and Sp1]. These observations may be
explained by the possibility that overexpression of any one of
the factors would result in sequestration of soluble poly(Q) and/
or its aggregates and saturation of its interacting sites, thus
preventing the recruitment of other factors. In SBMA patients,
some CBP-positive inclusions were negative for AR antibody,
perhaps due to complete sequestration of the mutant AR
aggregates by CBP (10). It is important to also consider the
sequestration of soluble forms of poly(Q) peptides as the
mediator of suppression versus that of their inclusions, because
we were not able to detect the Drosophila homolog of CBP in
the inclusions found in our fly model (not shown). Similarly, in
a comprehensive set of experiments using three different
HD mouse models, CBP could not be detected in the
poly(Q)-dependent inclusions (63).
Based on this hypothesis, therapeutic peptides could be
derived from such transcription factors that bind to and
sequester poly(Q) peptides, thus suppressing their toxicity.
Similarly, various segments of dMLF polypeptide could be
examined for co-localization with poly(Q) aggregates and
suppression of its toxicity and whether their interactions with
poly(Q) are dependent on other factors. Such experiments
could potentially provide biochemical targets or reagents for
therapeutic intervention in poly(Q) disorders. Indeed, various
peptides identified by phage display screen (64) or rational
design (65) have been shown to be effective in reducing the
toxicity of expanded poly(Q)s; though, in contrast to what has
been observed with dMLF and dHDJ1 (30,32), reduction of
poly(Q) toxicity by these peptides was associated with a delay
or reduction in the formation of poly(Q) aggregates.
Presently, due to lack of any detectable genetic interaction
between poly(Q) toxicity (and, for that matter, dmlf, as shown
here) and the dref pathway, it is not possible to speculate on the
role of the dref pathway in mediating poly(Q) toxicity or the
suppression effect by dmlf. Nevertheless, it is intriguing that
dMLF might be associated with a pathway involved in cell
proliferation and DNA replication (52). The human MLF1 gene
was originally identified as a portion of a chimeric product with
the nucleolar transport protein nucleophosmin (NPM), in the
chromosomal translocation t(3;5)(q25.1;q34), and is associated
with myelodysplastic syndrome (MDS) and acute myeloid
leukemia (AML) (51). A murine homolog (HLS7) is associated
with hematopoietic lineage switching from erythroid to
myeloid (66). Remarkably, several other proteins associated
with poly(Q) disease proteins are also involved in loss-of-
function mutations or chromosomal translocations associated
with various forms of cancer. For instance, inframe fusions of
CBP and the leukemia-related transcription factors MORF
(67), MLL (68,69) and MOZ (70), are associated with AML,
and CBP associates physically with BRCA1 (71). Mutations of
p53 are frequently associated with hematological malignancies
(72). Huntingtin interacting protein 1 (HIP1) has been found as
a chimeric gene with the platelet-derived growth factor b
receptor (PDGFbR) in a chromosomal translocation that causes
chronic myelomonocytic leukemia (CMML) (73). These
findings, and the lower incidence of cancer in individuals with
HD (74), point to the involvement of common molecules and
biochemical pathways in cancers and poly(Q) disorders.
MATERIALS AND METHODS
Fly maintenance, transformation and handling
Flies were maintained on corn meal/agar/yeast at 25C and
70% humidity. Microinjection solutions containing the trans-
genic constructs were composed of 13.5 mg transgenic vector,
4.5 mg pp25.1 transposase vector (75), 0.1 M sodium phosphate
buffer (pH 7.8) and 5 mM potassium chloride, in 50 ml aqueous
solution. Using Transjector 5246 and Femtotips II (Eppendorf),
the transgenic constructs were microinjected into 5–30 min old
w1118embryos reared at 18C. Several transgenic lines were
established for each construct. The UAS–lacZ trasgenic fly lines
that were used as controls are as follows: (Fig. 1) cytoplasmic
b-galactosidase (b-gal), genotype:w1118, P{w þ mC¼UAS–
lacZ}; (Figs. 4–7) nuclear b-gal, stock no. 3955, genotype w1118;
P{w þ mC¼UAS–lacZ.NZ}20b; (Figs. 4–8) nuclear b-gal,
stock no. 3956, genotype w1118; P{w þ mC¼UAS–lacZ.
NZ}J312 by Yash Hiromi; and (Fig. 7) cytoplasmic b-gal, stock
no. 1776, genotype w*; P{w þ mC¼UAS–lacZ.B}Bg4-1-2 by
Norbert Perrimon. For survival test, the flies were housed at 20 per
vial, using three to eight vials for each combination of transgenic
inserts. Every 4 days, the flies were transferred to new vials and
the dead flies were counted. These were defined by being
completely motionless or unable to climb onto the vial wall.
Plasmid constructs
pUAS–63Q was constructed in the same manner as pUAS–20Q
and pUAS–127Q as previously described (30). pUAS–
pros20Qtr and pUAS–pros127Qtr produced by digesting
full-length prospero constructs pUAS–pros20Q and pUAS–
pros127Q (30) with PstI and BstEII, and replacing the
PstI–BstEII fragment with an adapter fragment produced by
annealing the oligonucleotides PstI–BstEII.adapterF 50-G TAA
TAA GCC GCC ACC ATG GGG-30 and PstI–BstEII.adapterR
50-GTC ACC CCC ATG GTG GCG GCT TAT TAC TGC A-30
followed by its ligation into pUAS–pros20Q and pUAS–
pros127Q plasmids. p5GR–127Q, containing five tandem
GLASS response elements upstream of the 127Q sequence,
was derived from pUAS–127Q and pGMR.1N (40) by
removing the NheI–PstI fragment from pUAS–127Q, containing
the five UAS and the minimal Hsp70 promoter, and replacing it
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with a NheI–PstI-digested PCR fragment amplified from
pGMR.1N by the oligonucleotides GMR.PstIR 50-AAA ACT
GCA GTT AAA GGC ATT TCA AGG GTT TCC-30 and
GMR.NheIF 50-AAA AAA GCT AGC CCC AGT GGA AAC
CCT TGA AAT G-30. For p1GR-127Q, also derived from
pUAS–127Q, containing a single GLASS response element
upstream of the 127Q sequence, the NheI–PstI fragment from
pUAS–127Q was replaced with an NheI–PstI fragment
produced by annealing the oligonucleotides Glass1R.F
50-CTA GCC CCA GTG GAA ACC CTT GAA ATG CCT
TTA ACT GCA-30 and Glass1R.R 50-GTT AAA GGC ATT
TCA AGG GTT TCC ACT GGG G-30. Subsequently, the
intermediate p5GR and p1GR plasmids, containing five or one
GLASS response elements, were digested with PstI and
dephosphorylated by calf intestinal phosphatase (CIP; New
England Biolabs, Inc.). Into this dephosphorylated PstI site was
inserted a second NsiI–PstI-digested PCR-fragment, amplified
from the Hsp70 minimal promoter region of pUAS–127Q (30),
by the oligonucleotides Hsp70miniF 50-CCA AAA TGC ATA
GCG GAG ACT CTA GCG AGC GC-30 and pros11200R
50-GGT AGT TTG TCC AAT TAT GTC ACA CCA-30. This
completed the p5GR and p1GR plasmid constructs. To produce
p5GR–127Q or p1GR–127Q, the PstI–BamHI fragments of
p5GR or p1GR were replaced by similar PstI-BamHI fragments
from pUAS–127Q. PCR was performed in 200 ml thin-walled
tube strips on a Stratagene Robocycler Gradient 96 Hot Top.
The PCR reaction mixture contained 100 ng pGMR.1N or
pUAS–127Q template, 50 pmol of each primer, 1 cloned Pfu
buffer (Stratagene), 0.2 mM dNTP, 5% glycerol, 5% dimethyl-
sulfoxide (DMSO) and 1.25 units cloned Pfu DNA polymerase
(Stratagene) in a total volume of 62 ml aqueous solution. The
thermal cycling parameters were an initial single cycle of
denaturation at 95C for 3 min, followed by 35 cycles of
denaturation at 95C for 30 s, annealing at 65–80C for 1 min,
extension at 75C for 1 min, and, finally, a single cycle of
extension at 75C for 10 min. For pUAS–dmlf, the PstI–XhoI
fragments of GH20101 and LD47427 were cloned into the
pINDY6–UAS transgenic vector after the removal of its PstI–
XhoI fragment from its polyclonal site.
Immunofluorescence
Whole flies were submerged in Mirsky’s fixative (National
Diagnostics) for 1–2 min. They were then decapitated, and the
heads were placed in OCT 4583 embedding medium (Sakura
Finetek), frozen on dry ice and sectioned. Slides were dried on
a 50C hot plate for 30 s, then fixed in Mirsky’s fixative for
30 min, followed by fixing in paraformaldehyde (4%) for
10 min at room temperature, and washed three times within
10 min, using PBS/Tween-20 (0.1%). The sections were
blocked with 1% PBS/bovine serum albumin fraction V
(Sigma), and then covered with 1 mg/ml of primary polyclonal
Y-11 anti-HA (Santa Cruz Biotechnology, Inc.), primary
monoclonal M5 anti-Flag (Sigma-Aldrich), primary mono-
clonal D19-2F3-2 anti-b-gal (Roche Molecular), primary
monoclonal anti-ELAV 7D4E6 (Dr Kalpana White), primary
polyclonal anti-dCBP (Dr Sarah Smolik) or primary mono-
clonal anti-dMLF (Dr Masamitsu Yamaguchi) antibody in the
block solution for 2 h at room temperature. They were washed
3 5 min with PBS/Tween-20 (0.1%), covered with 4 mg/ml of
secondary FITC-labeled anti-rabbit or Cy3-labeled anti-mouse
antibody (Jackson ImmunoResearch Laboratories) in the block
solution for 1 h at room temperature, washed for 5 min with
PBS/Tween-20 (0.1%), covered with 0.5 mg/ml 40, 60-diamino-
2-phenylindole (DAPI) for 1 min, and washed 3 15 min with
the PBS/Tween-20. Finally, the sections were mounted in
0.1 mg/ml phenylenediamine (PDA)/0.5 mg/ml DAPI/90% gly-
cerol and viewed on a Zeiss Axioplan fluorescent microscope
and photographed by a SPOT-RT CCD digital camera using
SPOT 3.0.6 AppleEvent software. Confocal micrographs were
produced using an inverted Olympus IX70 microscope and
Fluoview software. Photoshop 6.0.1 and Canvas 7.0 softwares
were used to generate the figures.
Plastic tangential sections of the
ommatidia of the retina
The proboscises were cut off and whole fly heads were fixed in
paraformaldehyde (1%) and glutaraldehyde (1%) EM fixative
overnight at 4C. The heads were then rinsed with 0.1 M
phosphate buffer for 0.5 h and post-fixed with 1% osmium
tetroxide for 1–2 h. They were then rinsed with double-distilled
water for 10 min and dehydrated once in 50%, 70%, 85%, and
95% ethanol, for 5 min each, twice in 100% ethanol for 10 min,
and twice in 100% propylene oxide for 7 min. This was
followed by infiltrating the heads with 1 : 1 ratio of propylene
oxide: EM Bed-812 mixture (EM Bed-812 120 g, Epon 826
60 g, Epon 871 20 g, softener Dodecenylsuccinic anhydride
194 g, hardener Nadic methyl anhydride, mixed for 1 h and
then in pure EM Bed-812 mixture with N,N-benzyldimethy-
lamine (BDMA) for 3-4 hrs. The heads were embedded in pure
EM Bed-812 mixture in EM embedding mold and the matrix
was polymerized at 60C overnight. The blocks containing the
heads were sectioned at 1.2 mm on Sorval MT2-B Porter Blum
ultra-microtome. The sections were stained with toluidine blue
(1% toluidine blue and 1% borax in H2O) and mounted in
Permount (Fisher Scientific). The slides were viewed on a
Zeiss Axioplan microscope, using phase contrast filter and
100X oil-immersion objective, and photographed by SPOT-RT
CCD digital camera using SPOT 3.0.6 AppleEvent software.
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